Evaluation of varicella zoster virus specific immune response after varicella vaccine immunization in elderly patients with diabetes mellitus.

Evaluation of varicella zoster virus specific immune response after varicella vaccine immunization in elderly patients with diabetes mellitus. - Varicella zoster virus specific immune response induced by varicella vaccine immunization in old patients with diabetes mellitus.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004771

Enrollment

Registered

2010-12-21

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus

Interventions

Interventions:Immunization with 0.5ml of saline and 1 dose of pneumococcal vaccine (Pneumovax) to 25 patients with diabetes. Interventions:Immunization with 1 dose of live attenuated Varicella vaccin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 60 to 75 years of 50 patients with diabetes in HBA1c levels from 6 to 9.5

Exclusion criteria

Exclusion criteria: excluding criteria: patients with acute conditions; patients with underlying diseases, malignant disease, autoimmune diseases, and renal failure with serum creatinine greater than 2; smoker; treated with steroid, immunosuppressant drugs or antiplatelet drugs; with allergic reaction against varicella vaccine or pneumococcal vaccine; dermatological disorder unable to judge if skin test reaction or not; herpes zoster patients and patients within 5 years of primary 23-valent pneumococcal polysaccharides vaccine(PPSV23).

Design outcomes

Primary

Measure	Time frame
cell-mediated immunity(skin test reaction)	—

Secondary

Measure	Time frame
1. cell-mediated immunity; interferon-gamma (IFN-g) enzyme-linked immunospot (ELISPOT) 2.immunogenicity; immune adherence hemagglutination (IAHA) 3.Safety	—

Countries

Japan

Contacts

Public ContactTaku Satomi

Kitano hospital, The Tazuke Kofukai Medical Research Institute Clinical Research

rinshou@kitano-hp.or.jp06-6312-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026